ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01445379
Recruitment Status : Completed
First Posted : October 3, 2011
Last Update Posted : May 18, 2018
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)